95% of physicians support HF-specific single-pill combination therapy, and 83% of heart failure patients would take it to reduce pill burden and improve adherence.
Both physicians and patients demonstrate strong willingness to adopt a heart failure-specific polypill to reduce pill burden and potentially improve adherence.
Absolute Event Rate: 0% vs 0%
Abstract Background Single-pill combinations (SPC, polypills) have proven effective in cardiovascular areas, yet no such therapy exists for patients with heart failure (HF) despite substantial polypharmacy and pill burden in this population. Simplifying treatment through an HF-specific SPC containing key guideline-directed medical therapy (GDMT) components could improve adherence and outcomes. Methods Two prospective, electronic surveys were conducted between June and October 2025 to assess real-world attitudes toward a polypill in HF with ejection fraction ≤50%. The physician-oriented survey (22 questions) was distributed internationally and explored GDMT practices, perceived needs, barriers, and potential preferred composition of an HF dedicated SPC. The patient-oriented survey (11 questions) explored medication burden, adherence, and perceptions of a potential polypill use. Results A total of 250 physicians and 126 patients participated. Among physicians, 77% reported a clear need for strategies to simplify GDMT optimization in HFrEF, with cost (66%) and polypharmacy (54%) being selected as the most frequent barriers. Nearly all physicians (95%) recognized a real clinical need for an HF-specific SPC, and most perceived it as clinically useful (88%), logistically feasible (76%), and acceptable to patients (94%). Approximately 48% of physicians declared that they would use it regularly, and another 49% would use it in selected patients. The preferred composition of HF-specific SPC included a beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor (61.2%). Among patients, polypharmacy was common (70% taking ≥6 drugs daily), and 75% admitted to occasional non-adherence. Most responders (82%) would support a solution that reduces the pill burden, and 83% would take an HF-specific SCP if offered, particularly if there is no extra cost. Conclusions Both physicians and patients showed strong openness and willingness toward an HF-specific SPC, supporting further development and evaluation of HF-specific polypill strategies.
Biegus et al. (Sat,) reported a other. 95% of physicians support HF-specific single-pill combination therapy, and 83% of heart failure patients would take it to reduce pill burden and improve adherence.